Evidence map›Paper›PMID 38269649›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Stimulus-Responsive Copper Complex Nanoparticles Induce Cuproptosis for Augmented Cancer Immunotherapy.

Fuzhen Hu, Jia Huang, Tiejun Bing, Wenlong Mou, Duo Li, Hanchen Zhang, Yang Chen, Qionghua Jin, Yingjie Yu, Zhiying Yang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Ultrasound-activated nanoregulator enables CuJournal of nanobiotechnology · 2026
    Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Carbon dot sensitized CuJournal of nanobiotechnology · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fuzhen HuDepartment of Chemistry, Capital Normal University, Beijing, 100048, China.
Jia HuangDepartment of Hepatobiliary Surgery, China-Japan Friendship Hospital, Beijing, 100029, China.
Tiejun BingImmunology and Oncology Center, ICE Bioscience, Beijing, 100176, China.
Wenlong MouDepartment of Chemistry, Capital Normal University, Beijing, 100048, China.
Duo LiDepartment of Hepatobiliary Surgery, China-Japan Friendship Hospital, Beijing, 100029, China.
Hanchen ZhangBeijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China.
Yang ChenFaculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, 100039, China.
Qionghua JinDepartment of Chemistry, Capital Normal University, Beijing, 100048, China.ORCID 0000-0002-8492-4643
Yingjie YuState Key Laboratory of Organic-Inorganic Composites, Beijing Laboratory of Biomedical Materials, Beijing University of Chemical Technology, Beijing, 100029, China.
Zhiying YangDepartment of Hepatobiliary Surgery, China-Japan Friendship Hospital, Beijing, 100029, China.

Funding

Key project of science and technology plan of Beijing Education Commission KZ2021002808National High Level Hospital Clinical Research Funding & Elite Medical Professionals Project of China-Japan Friendship Hospital ZRJY2023-GG04National Key Clinical Specialty Construction Project General Surgery (Hepatobiliary Surgery) 2021-QLT-004National Natural Science Foundation of China 52373127Peking University Institutional Animal Care and Use Committee LA2021316
6 · The paper itself

Abstract

Cuproptosis, an emerging form of programmed cell death, has received tremendous attention in cancer therapy. However, the efficacy of cuproptosis remains limited by the poor delivery efficiency of copper ion carriers. Herein, copper complex nanoparticles (denoted as Cu(I) NP) are developed that can efficiently deliver copper complex into cancer cells to induce cuproptosis. Cu(I) NP demonstrate stimulus-responsive release of copper complexes, which results in mitochondrial dysfunction and promotes the aggregation of lipoylated dihydrolipoamide S-acetyltransferase (DLAT), leading to cuproptosis. Notably, Cu(I) NP not only induce cuproptosis, but also elicit robust immune responses to suppress tumor growth. Overall, this study provides a promising strategy for cuproptosis-based cancer therapy.

Indexed as

NanoparticlesNeoplasmsApoptosisCopperImmunotherapyCopperbioinorganic chemistrycuproptosisimmunotherapynanoparticlespancreatic cancer

Identifiers

PMID38269649
PMCPMC10987162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.